Resources from the same session
LBA80 - Siremadlin (S) and ribociclib (R) in patients (pt) with advanced well-differentiated/dedifferentiated liposarcomas (WD/DD LPS) and other molecularly selected cancers: Final analysis of the MEGAMOST “Ribociclib/HDM201” basket study
Presenter: Mehdi Brahmi
Session: Mini oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
1720MO - A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma
Presenter: Evan Rosenbaum
Session: Mini oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
1721MO - Safety and efficacy of olutasidenib, an IDH1 mutant inhibitor, for the treatment of recurrent/relapsed or locally advanced or metastatic IDH1 mutated chondrosarcoma
Presenter: Florence Duffaud
Session: Mini oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA80, 1720MO and 1721MO
Presenter: Joanna Szkandera
Session: Mini oral session: Sarcoma
Resources:
Slides
Webcast
1722MO - Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)
Presenter: Haibo Qiu
Session: Mini oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
1723MO - Axitinib plus avelumab in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) after failure of standard therapy: Single-arm phase II study (AXAGIST)
Presenter: Piotr Rutkowski
Session: Mini oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
1724MO - The final results of pulmonary resectable metastases of osteosarcoma with antiangiogenic and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Mini oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
1725MO - IMMUNOSARC II master trial (phase II of sunitinib and nivolumab): Results from the clear cell sarcoma (CCS) cohort: A GEIS, ISG, and UCL study
Presenter: Javier Martin-Broto
Session: Mini oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
1726MO - Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase I study
Presenter: Breelyn Wilky
Session: Mini oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
1727MO - Can proteomics predict metastatic relapse in leiomyosarcoma (LMS)? Development of an 8 protein signature in a >350 sample study including a validation cohort
Presenter: Elizabeth Connolly
Session: Mini oral session: Sarcoma
Resources:
Abstract
Slides
Webcast